Bracco's ProHance wins new indications

Bracco Diagnostics has received new indications from the Foodand Drug Administration for head and neck and pediatric CNS imagingfor its ProHance MRI agent. ProHance has been approved for usein children two years of age and older for MRI of the brain, spineand associated tissues at a dose of 0.1 mmol/kg. It is also nowindicated for the visualization of extracranial and extraspinalpathology of the head and neck region in adults at a dose of 0.1mmol/kg. Bracco Diagnostics is based in Princeton, NJ, and wasformed when Italy's Bracco bought Squibb Diagnostics.